Table 4.

NARA response compared between the 2 phase I studies with systemic administration reovirus

StudyPatients (N)Treatment schedulePeak level* ≤day 15Peak level ≥ 1/10.000Peak level ≥ 1/100.000
Vidal et al./White et al.35Dose escalation reovirus single agent days 1–5 of 28 day cycle20/32 (62.5%)31/32 (96.9%)23/32 (71.9%)
Lolkema et al.16Dose escalation reovirus day 1 of 21 day cycle combined with gemcitabine 1,000 mg/m2 day 1/81/12 (8.3%)5/14 (35.7%)0/14 (0%)

N.D. = not determined.

  • *Only patients that had their last sample beyond C1D15 were included.